Australia's most trusted
source of pharma news
Wednesday, 13 May 2026
Posted 13 May 2026 AM
An FDA advisory panel has voted against AstraZeneca’s camizestrant, casting uncertainty over the much-anticipated breast cancer therapy, although the drug remains under review in both the US and Australia.
Camizestrant, which has been under the TGA’s priority review since July 2025, belongs to a next-generation class of drugs known as oral SERDS, with A Menarini’s Orserdu the first to be approved for use in Australia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.